Skip to Main Content

A new multiple sclerosis medicine from Bristol Myers Squibb (BMY) was approved Thursday by the Food and Drug Administration — a decision that may end up helping Bristol shareholders first, before patients.

The newly approved drug, a once-daily pill to be sold under the brand name Zeposia, enters a multiple sclerosis treatment market crowded with rival, entrenched products that Bristol could find challenging to replace. Its future could be more promising in other autoimmune diseases.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED